RAZTAMRI

Serial Number 97855551
688

Registration Progress

Application Filed
Mar 24, 2023
Under Examination
Jan 14, 2025
Approved for Publication
May 14, 2024
Published for Opposition
Dec 3, 2024
Registered

Trademark Image

RAZTAMRI

Basic Information

Serial Number
97855551
Filing Date
March 24, 2023
Published for Opposition
December 3, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Jan 14, 2025
Application
Pending
Classes
005

Rights Holder

SYROS Pharmaceuticals, Inc.

03
Address
35 CambridgePark Drive, 4th Floor
Cambridge, MA 02140

Ownership History

SYROS Pharmaceuticals, Inc.

Original Applicant
03
Cambridge, MA

SYROS Pharmaceuticals, Inc.

Owner at Publication
03
Cambridge, MA

Legal Representation

Attorney
Ann Lamport Hammitte

USPTO Deadlines

All Deadlines Cleared

All 7 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

25 events
Date Code Type Description Documents
Jan 14, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 3, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 3, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 27, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 8, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 8, 2024 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Aug 6, 2024 PCGR O PETITION TO DIRECTOR GRANTED Loading...
Aug 6, 2024 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Aug 2, 2024 APET A ASSIGNED TO PETITION STAFF Loading...
May 22, 2024 ISPO Z WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST Loading...
May 14, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 14, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 7, 2024 TPDR I TEAS PETITION TO DIRECTOR RECEIVED Loading...
Apr 24, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 10, 2024 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Apr 10, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Apr 10, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Apr 10, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 10, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Dec 24, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Dec 24, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Dec 24, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 19, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 16, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 28, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical products for the treatment of hematologic cancers; pharmaceuticals for treatment of a myelodysplastic syndrome; pharmaceuticals for treatment of acute myeloid leukemia, which is also known as acute myelogenous leukemia and acute nonlymphocytic leukemia

Classification

International Classes
005